Deloitte to End GLP-1 Weight-Loss Coverage in January
The consulting firm's U.S. medical plans will stop covering GLP-1 medication for weight loss, alongside higher deductibles and out-of-pocket maximums.
Updated on Nov. 16, 2026 in Weight Loss

Live Poll
Do you think your employer is asking you to pay more for healthcare?
Deloitte will stop covering GLP-1 medication for weight loss through its U.S. medical plans starting January 2027, according to an internal benefits guide obtained by Business Insider. The change applies to Deloitte's Core, Domain and Enterprise professionals, and the firm is also raising deductibles and out-of-pocket maximums under most of its plans.
Why it matters
With roughly 181,000 U.S. employees affected, the change shows how large employers are shifting costs of costly GLP-1 drugs onto workers. Deloitte told staff the changes reflect the hard trade-offs of today's cost environment and the need for shared responsibility.
The benefits guide, reported by Business Insider, shows Deloitte's coverage change affects about 181,000 U.S. employees, with eMed program participants paying $125 per prescription. The exact number of employees currently using GLP-1 weight-loss medication and the size of the higher deductibles were not disclosed in the source.
The players
Deloitte
Deloitte is a multinational professional services firm offering audit, consulting, tax and advisory services to clients worldwide.
Business Insider
Business Insider is a U.S. digital news outlet focused on business, technology and finance reporting.
The details
Starting January, Deloitte's U.S. medical plans will no longer cover GLP-1 medication for weight loss, though coverage continues for patients using the drugs as prescribed for diabetes and other medical conditions. Employees seeking weight-loss support can use eMed, a virtual lifestyle program that includes coaching.
Timeline
November 16, 2026: Business Insider publishes a report on Deloitte's GLP-1 coverage ending.
January 2027: GLP-1 weight-loss coverage ends and higher deductibles and out-of-pocket maximums take effect.
Roadmap
Deloitte's decision follows a wave of large U.S. employers that have restricted GLP-1 weight-loss coverage as the cost of drugs such as Ozempic and Wegovy has climbed. The move places a major consulting firm among employers shifting more of those costs to workers through higher deductibles and narrower benefits.
Deloitte employees in the U.S. who use GLP-1 medication for weight loss will need to pay for it themselves beginning January 2027, unless they qualify under a diabetes or other medical condition. Those seeking support can use the eMed program at $125 per prescription contribution, which includes coaching.
The takeaway
Employees weighing weight-loss medication should check their plan's coverage details before open enrollment, since costs can shift sharply when employer benefits change. Asking HR about alternatives such as virtual programs can help manage expenses.
What happens next
Deloitte's GLP-1 weight-loss coverage ends and higher deductibles take effect in January 2027.
Further reading
For related coverage of medications and programs for losing weight, see Weight Loss.
Source note: This article includes information reported by Inc..
Live Poll
Do you think your employer is asking you to pay more for healthcare?






